AACR 2021 | CAR-T for Ewing’s sarcoma: impacts of the tumor microenvironment

Rimas J. Orentas, PhD, Seattle Children’s Research Institute, Seattle, WA, discusses the development of chimeric antigen receptor (CAR) T-cell therapies targeted against IL1RAP for the treatment of Ewing’s sarcoma. Preliminary studies of IL1RAP CAR-T in vivo indicated that novel approaches to enhancing efficacy are necessary. Furthermore, the role of the microenvironment and its impact on CAR-T cell therapy requires further investigation. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.